Ingrid G Winkler

List of Publications by Year
in descending order

86 papers	4,614 citations	31 h-index	67 g-index
88 all docs	88 docs citations	88 times ranked	5552 citing authors

#	Article	IF	Citations
1	Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. Leukemia, 2022, 36, 333-347.	3.3	10
2	InteligÃªncia artificial e virtualizaÃ§Ã£o em ambientes virtuais de ensino e aprendizagem. ETD: EducaÃ§Ã£o TemÃ¡tica Digital, 2021, 23, 2-19.	0.0	3
3	Adhesion to Eâ€selectin primes macrophages for activation through AKT and mTOR. Immunology and Cell Biology, 2021, 99, 622-639.	1.0	2
4	Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches. Experimental Hematology, 2021, 100, 12-31.e1.	0.2	8
5	Macrophages form erythropoietic niches and regulate iron homeostasis to adapt erythropoiesis in response to infections and inflammation. Experimental Hematology, 2021, 103, 1-14.	0.2	9
6	Prostacyclin is an Endosteal Bone Marrow Niche Component and its Clinical Analog Iloprost Protects Hematopoietic Stem Cell Potential During Stress. Stem Cells, 2021, 39, 1532-1545.	1.4	4
7	Bacterial Lipopolysaccharides Suppress Erythroblastic Islands and Erythropoiesis in the Bone Marrow in an Extrinsic and G- CSF-, IL-1-, and TNF-Independent Manner. Frontiers in Immunology, 2020, 11, 583550.	2.2	13
8	Acute Myeloid Leukemia Chemo-Resistance Is Mediated by E-selectin Receptor CD162 in Bone Marrow Niches. Frontiers in Cell and Developmental Biology, 2020, 8, 668.	1.8	32
9	Imaging flow cytometry reveals that granulocyte colony-stimulating factor treatment causes loss of erythroblastic islands in the mouse bone marrow. Experimental Hematology, 2020, 82, 33-42.	0.2	23
10	Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nature Communications, 2020, 11, 2042.	5.8	99
11	MACROPHAGE INVOLVEMENT IN THE RESPONSE OF ACUTE MYELOID LEUKAEMIA TO CHEMOTHERAPY. Experimental Hematology, 2019, 76, S70.	0.2	0
12	Single-Cell Transcriptional Profiling of Aortic Endothelium Identifies a Hierarchy from Endovascular Progenitors to Differentiated Cells. Cell Reports, 2019, 27, 2748-2758.e3.	2.9	96
13	HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR. Blood Advances, 2019, 3, 406-418.	2.5	16
14	Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor. Blood, 2019, 134, 4469-4469.	0.6	2
15	Blocking Vascular Niche E-Selectin Dampens AML Stem Cell Regeneration/Survival Potential In Vivo By Inhibiting MAPK/ERK and PI3K/AKT Signalling Pathways. Blood, 2019, 134, 2657-2657.	0.6	2
16	CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche. Blood, 2019, 134, 907-907.	0.6	0
17	Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment. Blood, 2018, 132, 735-749.	0.6	69
18	Prostaglandin I2 in the Endosteal Bone Marrow Niche As a Novel Regulator of Hematopoietic Stem Cells. Blood, 2018, 132, 2575-2575.	0.6	3

#	Article	IF	Citations
19	Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature. Blood, 2018, 132, 4552-4552.	0.6	0
20	Cellular players of hematopoietic stem cell mobilization in the bone marrow niche. International Journal of Hematology, 2017, 105, 129-140.	0.7	78
21	<scp>CD169</scp> ⁺ macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer. Journal of Pathology, 2016, 239, 218-230.	2.1	37
22	Fms-like tyrosine kinase 3 (Flt3) ligand depletes erythroid island macrophages and blocks medullar erythropoiesis in the mouse. Experimental Hematology, 2016, 44, 207-212.e4.	0.2	20
23	358 Alleviation of Acute Drug-Induced Liver Injury Following Acetaminophen Overdose by Therapeutic Blockade of E-Selectin in Preclinical Mouse Model. Gastroenterology, 2016, 150, S1029.	0.6	0
24	Radio-resistant recipient bone marrow (BM) macrophages (MACS) are necessary for hematopoietic stem cell (HSC) engraftment post transplantation. Experimental Hematology, 2016, 44, S43-S44.	0.2	1
25	Prostaglandin I2 is produced in the endosteal region of the bone marrow and protects haematopoietic stem cell from irradiation stress. Experimental Hematology, 2016, 44, S102-S103.	0.2	1
26	Therapeutic blockade of macrophage colony stimulating factor (CSF-1) delays leukaemia progression of AML in mice in vivo. Experimental Hematology, 2016, 44, S42.	0.2	0
27	Hematopoietic stem cell mobilization and erythropoiesis suppression in response to lipopolysaccharides involve two distinct TLR4-depedent mechanisms with different requirement for G-CSF receptors. Experimental Hematology, 2016, 44, S60.	0.2	2
28	Cell Adhesion Molecules in Normal and Malignant Hematopoiesis: from Bench to Bedside. Current Stem Cell Reports, 2016, 2, 356-367.	0.7	16
29	Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak. Experimental Hematology, 2016, 44, 303-314.e1.	0.2	18
30	Vascular E-Selectin Protects Leukemia Cells from Chemotherapy By Directly Activating Pro-Survival NF-Kb Signalling - Therapeutic Blockade of E-Selectin Dampens NF-Kb Activation. Blood, 2016, 128, 2823-2823.	0.6	7
31	Suppression of Medullar Erythropoiesis in Response to Bacterial Lipopolysaccharides (LPS) Involves Two Distinct TLR4-Dependent Mechanisms with Contrasted Requirements for G-CSF Receptors. Blood, 2016, 128, 546-546.	0.6	0
32	Therapeutic Blockade of Macrophage Colony Stimulating Factor (CSF-1) Delays AML Progression in Mice In Vivo. Blood, 2016, 128, 2835-2835.	0.6	0
33	Autologous haematopoietic stem cell transplantation requires recipient BM macrophages. Experimental Hematology, 2015, 43, S71.	0.2	0
34	Neurological heterotopic ossification following spinal cord injury is triggered by macrophageâ€mediated inflammation in muscle. Journal of Pathology, 2015, 236, 229-240.	2.1	131
35	Tissue engineered humanized bone supports human hematopoiesisÂinÂvivo. Biomaterials, 2015, 61, 103-114.	5.7	62
36	Hypoxia inducible factor (HIF)-2Î± accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 2015, 29, 2075-2085.	3.3	36

#	Article	IF	Citations
37	HIF-1Î± is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1Î±. Leukemia, 2015, 29, 1366-1378.	3.3	45
38	Mobilization of CD8+ Central Memory T-Cells with Enhanced Reconstitution Potential in Mice By a Combination of G-CSF and GMI-1271-Mediated E-Selectin Blockade. Blood, 2015, 126, 512-512.	0.6	1
39	Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood, 2014, 123, 2682-2690.	0.6	103
40	Bacterial liposaccharides block medullary erythropoiesis by depleting F4/80+ VCAM1+ CD169+ ER-HR3+ Ly-6G+ erythroid island macrophages in the bone marrow. Experimental Hematology, 2014, 42, S40.	0.2	0
41	Mobilization with granulocyte colony-stimulating factor blocks medullar erythropoiesis by depleting F4/80+VCAM1+CD169+ER-HR3+Ly6G+ erythroid island macrophages in the mouse. Experimental Hematology, 2014, 42, 547-561.e4.	0.2	82
42	Mobilisation of Reconstituting HSC Is Boosted By Synergy Between G-CSF and E-Selectin Antagonist GMI-1271.. Blood, 2014, 124, 317-317.	0.6	2
43	Vascular Niche E-Selectin Protects Acute Myeloid Leukaemia Stem Cells from Chemotherapy. Blood, 2014, 124, 620-620.	0.6	20
44	It takes nerves to recover from chemotherapy. Nature Medicine, 2013, 19, 669-671.	15.2	18
45	Pharmacological stabilization of hypoxia-inducible factor-1Î± (HIF-1Î±) enhances hematopoietic stem cell mobilization in response to G-CSF and plerixafor. Experimental Hematology, 2013, 41, S73.	0.2	0
46	Mobilising doses of G-CSF stop medullary erythropoiesis by depleting CD169+ macrophages. Experimental Hematology, 2013, 41, S59.	0.2	0
47	Nichotherapy for stem cells: There goes the neighborhood. BioEssays, 2013, 35, 183-190.	1.2	14
48	A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity. Gut, 2013, 62, 594-605.	6.1	48
49	Pharmacologic stabilization of HIF-1Î± increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood, 2013, 121, 759-769.	0.6	109
50	B-lymphopoiesis is stopped by mobilizing doses of G-CSF and is rescued by overexpression of the anti-apoptotic protein Bcl2. Haematologica, 2013, 98, 325-333.	1.7	38
51	Engraftment Outcomes after HPC Co-Culture with Mesenchymal Stromal Cells and Osteoblasts. Journal of Clinical Medicine, 2013, 2, 115-135.	1.0	3
52	Administration Of E-Selectin Antagonist GMI-1271 Improves Survival After High-Dose Chemotherapy By Alleviating Mucositis and Accelerating Neutrophil Recovery. Blood, 2013, 122, 2266-2266.	0.6	7
53	Hypoxia Inducible Factor (HIF)-2Î± Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. Blood, 2013, 122, 2895-2895.	0.6	0
54	Mobilizing Doses Of G-CSF Stop Medullary Erythropoiesis By Depleting F4/80+ VCAM1+ ER-HR3+ CD169+ Erythroid-Island Macrophages. Blood, 2013, 122, 309-309.	0.6	0

#	Article	IF	Citations
55	Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nature Medicine, 2012, 18, 1651-1657.	15.2	364
56	Flow Cytometry Analysis of Cell Cycling and Proliferation in Mouse Hematopoietic Stem and Progenitor Cells. Methods in Molecular Biology, 2012, 844, 31-43.	0.4	16
57	Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia, 2012, 26, 1594-1601.	3.3	136
58	Mobilization of Hematopoietic Stem Cells by Depleting Bone Marrow Macrophages. Methods in Molecular Biology, 2012, 904, 117-138.	0.4	23
59	Flow Cytometry Measurement of Bone Marrow Perfusion in the Mouse and Sorting of Progenitors and Stems Cells According to Position Relative to Blood Flow In Vivo. Methods in Molecular Biology, 2012, 844, 45-63.	0.4	8
60	FG-4497, a Pharmacological Stabilizer of HIF-1Î± Protein, Synergistically Enhances Hematopoietic Stem Cells (HSC) Mobilization in Response to G-CSF and Plerixafor. Blood, 2012, 120, 216-216.	0.6	2
61	Interaction of c-Myb with p300 Is Required for the Induction of Acute Myeloid Leukemia by Human AML Oncogenes, and Represents a Potential Therapeutic Target.. Blood, 2012, 120, 2402-2402.	0.6	0
62	Hierarchy of immature hematopoietic cells related to blood flow and niche. Current Opinion in Hematology, 2011, 18, 220-225.	1.2	41
63	Mobilisation strategies for normal and malignant cells. Pathology, 2011, 43, 547-565.	0.3	8
64	Impairment of Hematopoietic Stem Cell (HSC) Niche by G-CSF Is Associated with Rapid Mobilization of Serially Reconstituting HSC and Reduced Competitive Repopulation of Mobilized Bone Marrow. Blood, 2011, 118, 1889-1889.	0.6	2
65	Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood, 2010, 116, 375-385.	0.6	228
66	Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood, 2010, 116, 4815-4828.	0.6	695
67	The endosteal â€˜osteoblasticâ€™ niche and its role in hematopoietic stem cell homing and mobilization. Leukemia, 2010, 24, 1979-1992.	3.3	243
68	Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Regulates Hematopoiesis and Bone Formation In Vivo. PLoS ONE, 2010, 5, e13086.	1.1	47
69	OsteoMacs maintain the endosteal hematopoietic stem cell niche and participate in mobilization. Bone, 2009, 44, S32-S33.	1.4	0
70	Mobilization of hematopoietic stem cells: state of the art. Current Opinion in Organ Transplantation, 2008, 13, 53-58.	0.8	66
71	The Role of Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) in Hematopoiesis. Blood, 2008, 112, 1362-1362.	0.6	0
72	Granulocyte Colony-Stimulating Factor and an RAR?? Specific Agonist, VTP195183, Synergize to Enhance the Mobilization of Hematopoietic Progenitor Cells. Transplantation, 2007, 83, 375-384.	0.5	21

#	Article	IF	Citations
73	Hematopoietic Progenitor Cell Mobilization Results in Hypoxia with Increased Hypoxia-Inducible Transcription Factor-1Î± and Vascular Endothelial Growth Factor A in Bone Marrow. Stem Cells, 2007, 25, 1954-1965.	1.4	128
74	Absence of E-Selectin at the Vascular Niche Delays Hematopoietic Stem Cell Turn-Over.. Blood, 2007, 110, 609-609.	0.6	2
75	Mechanisms of hematopoietic stem cell mobilization: When innate immunity assails the cells that make blood and bone. Experimental Hematology, 2006, 34, 996-1009.	0.2	118
76	Contrasting effects of P-selectin and E-selectin on the differentiation of murine hematopoietic progenitor cells. Experimental Hematology, 2005, 33, 232-242.	0.2	25
77	Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization. Journal of Experimental Medicine, 2005, 201, 1077-1088.	4.2	96
78	G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood, 2005, 106, 3020-3027.	0.6	444
79	The Inhibition of the Osteoblast Niche during Hematopoietic Stem Cell Mobilization Is an Indirect Effect Involving Mature Bone Marrow Leukocytes, IL6 and Soluble IL6 Receptor.. Blood, 2005, 106, 1966-1966.	0.6	1
80	Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of PSGL-1. Blood, 2004, 103, 1685-1692.	0.6	39
81	Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Experimental Hematology, 2003, 31, 109-117.	0.2	176
82	Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Experimental Hematology, 2002, 30, 440-449.	0.2	265
83	Antibody to Human Foamy Virus Not Detected in Individuals Treated with Blood Products or in Blood Donors. Vox Sanguinis, 2000, 79, 118-119.	0.7	3
84	Construction of Infectious Feline Foamy Virus Genomes: Cat Antisera Do Not Cross-Neutralize Feline Foamy Virus Chimera with Serotype-Specific Env Sequences. Virology, 2000, 266, 150-156.	1.1	46
85	Detection and Molecular Characterisation of Feline Foamy Virus Serotypes in Naturally Infected Cats. Virology, 1998, 247, 144-151.	1.1	56
86	A rapid streptavidin-capture ELISA specific for the detection of antibodies to feline foamy virus. Journal of Immunological Methods, 1997, 207, 69-77.	0.6	24